Media coverage about Synlogic (NASDAQ:SYBX) has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Synlogic earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6932918740469 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Synlogic (NASDAQ SYBX) traded up $0.15 during trading hours on Friday, reaching $10.98. The company’s stock had a trading volume of 205,836 shares, compared to its average volume of 266,611. Synlogic has a 12-month low of $8.76 and a 12-month high of $23.00. The firm has a market cap of $231.91, a P/E ratio of -1.16 and a beta of 2.91.
SYBX has been the topic of several recent analyst reports. Zacks Investment Research downgraded Synlogic from a “hold” rating to a “sell” rating in a report on Wednesday, November 22nd. ValuEngine downgraded Synlogic from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Wedbush initiated coverage on Synlogic in a report on Monday, November 27th. They set an “outperform” rating and a $20.00 price objective on the stock. Finally, Piper Jaffray Companies initiated coverage on Synlogic in a report on Monday, January 29th. They set an “overweight” rating and a $16.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $18.75.
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.